Overview
Symbiotec Pharmalab IPO is a mainboard IPO scheduled to open for subscription on — and closed on —. The issue aggregates ₹2,180 Cr.
IPO Details
Symbiotec Pharmalab IPO is a mainboard initial public offering scheduled to open for subscription on Both. The issue has a price band of TBA per equity share with a lot size of TBA shares, translating to a minimum retail investment of TBA.
The issue aggregates ₹2,180 Cr, and subscription dates are yet to be announced. Allotment is expected on — and the equity shares are scheduled to list on —.
- Type
- Mainboard
- Status
- upcoming
- Price band
- TBA
- Face value
- ₹10 (typical)
- Lot size
- —
- Min investment (Retail)
- TBA
- Issue size
- ₹2,180 Cr
- Fresh issue
- ₹150 Cr
- OFS
- ₹2,030 Cr
- Exchange
- Both
- ISIN
- TBA
- Sector
- Pharmaceuticals
Market Lot
Market lot details will be available once the price band and lot size are finalised in the Red Herring Prospectus.
IPO Reservation
Per SEBI guidelines, Symbiotec Pharmalab IPO reserves shares across investor categories as follows. Final allotment percentages may vary slightly based on the final issue document.
| Category | % Reserved | Notes |
|---|---|---|
| QIB (Qualified Institutional Buyers) | Not more than 50% | Mutual funds, FIIs, banks, insurance |
| NII / HNI (Non-Institutional) | Not less than 15% | Bids ≥ ₹2 lakh |
| Retail (RII) | Not less than 35% | Bids up to ₹2 lakh |
Important Dates
- Issue Open— · Subscription opens
- Issue Close— · Subscription closes
- Allotment— · Basis of allotment finalised
- Refunds Initiated— · Funds released for non-allottees
- Listing Date— · Shares debut on the exchange
Grey Market Premium
Grey Market Premium for Symbiotec Pharmalab is yet to be tracked. We update GMP from multiple grey market sources during the subscription window. Bookmark this page and check IPO GMP Today for live updates.
Subscription Status
Symbiotec Pharmalab IPO subscription tracking will go live once the subscription window opens. Category-wise data (Retail / NII / QIB / Employee) will be available on IPO Subscription Status.
Allotment Status
Symbiotec Pharmalab IPO allotment will be finalised by the registrar (TBA) on —. Check your allotment status using your PAN, application number, or DP ID via our allotment status checker or directly on the registrar's website.
If allotment fails, the blocked funds via ASBA / UPI mandate are released back within 24-48 hours. Applying through multiple demat accounts in family members' names improves chances on oversubscribed IPOs.
About Symbiotec Pharmalab
Promoter & Holding Pattern
The promoter and promoter group hold the majority stake in Symbiotec Pharmalab prior to the IPO. Post-listing, this percentage will reduce as new equity shares are issued to the public. Detailed pre-IPO and post-IPO promoter holding data will be updated once the Red Herring Prospectus is finalised with SEBI.
Objects of the Issue
Symbiotec Pharmalab IPO proceeds will be utilised across the following objectives, as disclosed in the Red Herring Prospectus:
| Purpose | Amount (₹ Cr) | % of Issue |
|---|---|---|
| Prepayment / repayment of outstanding borrowings — debt reduction at company level (fresh issue) | 150 | 7.00% |
| Offer for Sale by existing shareholders — promoter and PE / sponsor monetisation | 2,030 | 93.00% |
Financial Performance
Symbiotec Pharmalab's three-year financials — revenue, PAT, assets, net worth — will be displayed here based on audited numbers from the Red Herring Prospectus. Year-on-year growth, EBITDA margins, debt-to-equity progression, and RoNW together form the basis for valuation comparison.
Valuation Snapshot
Key valuation metrics for Symbiotec Pharmalab — RoE, RoCE, EBITDA margin, PAT margin, debt-to-equity, EPS, P/E ratio, RoNW, NAV — will be updated based on FY25 numbers from the Red Herring Prospectus.
Peer Comparison
Listed peers in the Pharmaceuticals sector with key valuation metrics:
| Company | EPS (₹) | P/E Ratio | RoNW (%) | NAV (₹) | Income (₹ Cr) |
|---|---|---|---|---|---|
| Divi's Laboratories | — | — | — | — | — |
| Laurus Labs | — | — | — | — | — |
| Suven Pharmaceuticals | — | — | — | — | — |
| Cohance Lifesciences | — | — | — | — | — |
Anchor Investors
Anchor investor bidding for Symbiotec Pharmalab typically opens one working day before the issue opens to the public. Anchor investors — mutual funds, FIIs, sovereign wealth funds, and insurance companies — collectively subscribe to a portion of the QIB segment. Their participation signals institutional confidence. Anchor list and total amount will be updated once SEBI publishes the anchor filing.
Lead Managers (Merchant Bankers)
Book-Running Lead Managers (BRLMs) for Symbiotec Pharmalab will be listed once confirmed in the Red Herring Prospectus. Lead managers oversee pricing, marketing, and underwriting — typically Kotak, ICICI Securities, Axis Capital, HDFC, SBI Caps, JP Morgan, or Citigroup.
IPO Registrar
The registrar for Symbiotec Pharmalab IPO will be confirmed in the Red Herring Prospectus. The registrar handles allotment, refunds, and dematerialisation of shares.
Editorial Review
How to Apply for Symbiotec Pharmalab IPO
- Open broker app — Zerodha, Upstox, Angel One, Groww, 5paisa, ICICI Direct, or any other SEBI-registered broker. Navigate to the IPO section.
- Select Symbiotec Pharmalab IPO during the bidding window (— – —).
- Enter bid details — minimum TBA shares per lot. Retail investors are recommended to bid at cut-off price (upper band).
- Submit UPI ID linked to a SEBI-approved bank.
- Approve UPI mandate from your UPI app within the deadline. Bid amount is blocked, not debited.
- Await allotment on —.
- Listing day — shares list on Both on —.